Hematology CME

The BoardVitals Hematology and Oncology CME Review offers clinicians 27 AMA PRA Category 1 Credits^TM, 27 ABIM MOC points, and over 500 Hematology and Oncology board review questions. The questions cover key topics including Breast Cancer, Gynecologic Cancer, and Transfusion Medicine. This question bank will assist clinicians with Hematology and Oncology certification and recertification.

The BoardVitals Hematology and Oncology CME Review also features:

• Quick and Convenient CME
• Computer, phone, and tablet access
• Constantly updated up-to-date questions
• Questions that are targeted specifically to the exam
• Online CME tracker
• 100% Pass Guarantee
• Statistical comparison to other Hematology and Oncology test-takers (Nationally)

After completing this activity, you should be able to:

• Make a diagnosis
• Order and interpret results
• Assess risk, determine prognosis, and apply principles from epidemiologic studies
• Describe the underlying pathophysiology of disease and basic science knowledge

Target Audience: Hematologists and Oncologists

Maximize your CME allowance with MDCalc and get up to a $3,500 bonus gift card of your choice. Earn AMA PRA Category 1 Credits^TM for clinical content on 150+ calculators across multiple medical specialties. Easily earn and redeem CME at the point-of-care, online on our website or mobile app. Over 1 million medical professionals use MDCalc’s 550+ tools daily to support clinical decision making at the bedside.

Learn Now: Thrombosis CME from the Experts

This online CME course from the North American Thrombosis Forum provides a comprehensive review of the most significant changes and advances impacting the care of patients who have — or are at risk for — thrombotic disorders. World-renowned experts and leading clinical faculty share key updates on the prevention, diagnosis, and treatment of thrombosis and related conditions.

Thrombosis and Thromboembolism is continuing medical education that will help you to:

• Identify the etiology and pathophysiology of atherothrombosis
• Recognize the link between inflammation and thrombotic illnesses
• Explain new tools for stroke prevention and prediction in atrial fibrillation
• Identify the optimal duration of anticoagulation for PE and DVT
• Provide advanced therapies such as thrombolysis, catheter-directed therapy, and surgical embolectomy
• Explain the connection between diabetes, metabolic syndrome, and major adverse cardiac events
• Provide patients with useful insights into how a heart-healthy diet can help prevent thrombosis
• Manage a high-risk pregnancy
• And more…

Stay on top of your game with the StatPearls Physician Unlimited CME programs. With 6,046 activities, StatPearls is the largest CME provider in the world. These Pub-Med Indexed articles are categorized into 162 specialty areas which lets you better access activities that will make the biggest impact on your practice. One subscription allows access to all the activities, including all state-requirements.

Pricing Options

• 6 Month subscription: All 6,339 CME Activities – $249 per 6 months
• Annual subscription: All 6,339 CME Activities – $349 per 1 year
• Lifetime: All 6,339 CME Activities + Access to Board Reviews Forever – $1999

Elevate Your Hematology and Oncology CME

The Brigham and Dana-Farber Board Review and Comprehensive Update in Hematology and Oncology is a case-based online CME course focused on improving overall knowledge and clinical competency. Prep for your board exam and stay current on basic principles, changing guidelines and therapeutic strategies. Practice improvement areas featured in the continuing medical education program include:

• Acquired/Congenital Bone Marrow Failure
• Thalassemia/Hemoglobinopathies
• Transfusion Medicine
• New Therapies (Pharmacology)
• Infections of the Immunocompromised
• Hematologic Malignancies (Acute/Chronic Leukemias; Myeloma/Lymphomas)
• Thoracic Oncology (Head/Neck/Lung/Thyroid)
• and many more…

Elevate Your Hematology CME

The Brigham and Dana-Farber Board Review and Comprehensive Update in Hematology online CME program brings together a distinguished group of experts to present current diagnostic and therapeutic strategies. Enhance patient care and prep for your board exam with topics like molecular genetics, leukemia, bone marrow failures, transfusion medicine, and more. It’s continuing medical education that will help you to better:

• Apply current/recommended hematology guidelines in clinical practice
• Perform differential diagnosis of complex hematologic disorders
• Identify and apply current therapeutic options for hematologic disorders
• Evaluate and interpret up-to-date literature relevant to clinical practice in hematology
• Illustrate knowledge of pathophysiology of hematology disorders
• Apply knowledge gained to the ABIM certification/recertification

This program is also available as part of the combined Brigham and Dana-Farber Board Review and Comprehensive Update in Hematology and Oncology CME course found here.

Medical videos & lectures explained clearly by world-class instructors.

Memorable illustrations, clinical scenarios, and passionate instructors set MedCram apart from other online medical lectures.

We prioritize the most important clinically relevant and practical information for clinical practice.

Understanding medicine has never been so simplified.

Activity Description / Statement of Need:

In this online, self-learning activity:

Thalassemias belong to a group of recessively inherited blood disorders characterized by little or no hemoglobin production and chronic anemia of varying severity. Alpha-thalassemia (AT) is most commonly found in people of Mediterranean, Middle Eastern, Asian, and North African descent. Worldwide, 5% of people are AT carriers, with a much higher prevalence in certain regions (eg, up to 23% in Southeast Asia). AT is typically caused by deletions of one or more α-globin genes, of which there are 4 in total, leading to reduced or abolished α-globin production; nondeletional forms of AT can also occur and are generally more severe. The loss of functional α-globin disrupts the globin chain equilibrium, leading to excess γ- and β-globin chain formation and causing ineffective erythropoiesis.

Target Audience:

The following healthcare professionals: hematologists; physician assistants, nurse practitioners, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who may clinically encounter patients with AT.

Target Audience: Hematologists

Activity Description / Statement of Need:
In this online, self-learning activity:

Transthyretin-mediated amyloidosis (ATTR) is a progressive, multisystem, life-threatening disorder characterized by the extracellular deposition of misfolded, insoluble amyloid fibrils. The role of the TTR protein is to transport thyroxine and retinol-binding proteins, and it is vital for cognition, nerve regeneration, and axonal growth. TTR itself is innately amyloidogenic even without the presence of genetic mutations, which may account for wild-type ATTR (wtATTR), while a hereditary form of ATTR (hATTR) may be passed to offspring through autosomal dominant inheritance. Left untreated, the average life expectancy of ATTR is 3 to 15 years from symptom onset.

Target Audience:
The following HCPs: neurologists, cardiologists, and hematologists; physician assistants, nurse practitioners, and pharmacists in the aforementioned areas of specialty; and any other HCPs with an interest in or who may clinically encounter patients with ATTR.